宽颈动脉瘤栓塞与重建辅助神经血管支持试验(ANSWER)更新:1年安全性与血管造影结果
ANSWER前瞻性试验纳入34例宽颈分叉部动脉瘤患者(基底动脉尖和颈动脉末端),评估PulseRider辅助栓塞的1年安全性与疗效。1年时无装置移位或症状性支架内狭窄,Raymond-Roy I级闭塞从治疗时53%进展至6个月61%和12个月67%,充分闭塞(I/II级)从6个月88%升至12个月90%,无再通,1例迟发性缺血事件,90%患者mRS 0-2。作者认为1年结果示动脉瘤稳定且安全性可接受,但需更大样本其他部位的前瞻性数据来比较PulseRider与替代治疗。
要点
- 1年时Raymond-Roy I级闭塞67%、I/II级闭塞90%,无再通。
- 1年无装置移位或症状性支架内狭窄,仅1例迟发性缺血事件。
- 90%患者达到良好临床结局(mRS 0-2)。
核心结论
- ANSWER试验更新1年结果显示,基底动脉尖和颈动脉末端动脉瘤经PulseRider治疗后的动脉瘤稳定性和安全性可接受。
研究设计与样本
- 前瞻性试验(ANSWER),纳入34例患者(29女,5男),平均年龄60.9岁,评估PulseRider治疗宽颈分叉部动脉瘤的12个月临床和影像终点。
关键影像表现/征象
- 平均动脉瘤高度范围2.4-15.9 mm,平均瘤颈宽度5.2 mm(范围2.3-11.6 mm)。
- 1年时无装置移位或症状性支架内狭窄。
- 无再通病例观察到。
- 1例迟发性缺血事件。
诊断标准与关键数值
- Raymond-Roy I级闭塞率:治疗时53%,6个月61%,12个月67%。
- 充分闭塞(Raymond-Roy I/II级):6个月88%,12个月90%。
- 良好临床结局(mRS 0-2)占90%。
局限性
- 需更大样本的其他部位动脉瘤前瞻性数据来评估PulseRider与宽颈分叉部动脉瘤替代治疗的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The safety and efficacy of the PulseRider for the treatment of wide-neck, bifurcation aneurysms at the basilar and carotid terminus locations were studied in a prospective trial, the Adjunctive Neurovascular Support of Wide-Neck Aneurysm Embolization and Reconstruction (ANSWER) trial, reporting on initial 6-month angiographic and clinical results. This report provides insight into the longer term durability and safety with 12-month data.
MATERIALS AND METHODS: Aneurysms treated with the PulseRider among enrolled sites were prospectively studied. Updated 12-month data on clinical and imaging end points are included.
RESULTS: Thirty-four patients were enrolled (29 women, 5 men) with a mean age of 60.9 years. The mean aneurysm height ranged from 2.4 to 15.9 mm with a mean neck size of 5.2 mm (range, 2.3-11.6 mm). At 1 year, there were no device migrations or symptomatic in-stent stenoses. Raymond-Roy I occlusion was achieved in 53% of cases at the time of treatment and progressed to 61% and 67% at 6 and 12 months, respectively. Adequate occlusion (Raymond-Roy I/II) progressed from 88% at 6 months to 90% at 12 months. No recanalizations were observed. There was 1 delayed ischemic event. Good outcome (mRS 0-2) was achieved in 90% of patients.
CONCLUSIONS: The updated 1-year results from the ANSWER trial demonstrate aneurysm stability and an acceptable safety profile for aneurysms treated at the basilar apex and carotid terminus. Prospective data from a larger set of aneurysms treated at other locations are required to assess how treatment with PulseRider compares with alternatives for treating wide-neck bifurcation aneurysms.
引用
- Spiotta AM, Chaudry MI, Turner RD, et al. An Update on the Adjunctive Neurovascular Support of Wide-Neck Aneurysm Embolization and Reconstruction Trial: 1-Year Safety and Angiographic Results. AJNR Am J Neuroradiol. 2018. PMID: 29599174. doi:10.3174/ajnr.A5599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。